The $590,000 grant will support the program which focuses on the impact of maternal immunity against RSV on the generation of a protective immune response in newborns.
GenVec RSV program head and research senior director Jason Gall said the funds will be used to further advance the company’s novel pediatric RSV vaccine.
"RSV has long been recognized as a priority target for vaccine development, and our program has the potential to address this significant unmet medical need," Gall added.